Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Beats Estimates By $0.06 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06, Zacks reports. Vanda Pharmaceuticals had a negative return on equity of 3.02% and a negative net margin of 8.59%. Vanda Pharmaceuticals updated its FY 2030 guidance to EPS and its FY 2025 guidance to EPS.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA traded down $0.05 during midday trading on Thursday, hitting $4.70. 937,216 shares of the company traded hands, compared to its average volume of 582,002. The stock has a 50-day moving average price of $4.63 and a 200 day moving average price of $4.87. The firm has a market cap of $274.06 million, a P/E ratio of -16.79 and a beta of 0.74. Vanda Pharmaceuticals has a 12-month low of $3.71 and a 12-month high of $6.75.

Analyst Ratings Changes

VNDA has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Vanda Pharmaceuticals in a research note on Tuesday, February 4th. StockNews.com began coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.